scholarly journals Emerging concepts and recent advances in basal cell carcinoma

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2085 ◽  
Author(s):  
Mariam Totonchy ◽  
David Leffell
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Basal Layer ◽  
Standard Of Care ◽  
Surgical Excision ◽  
Surgical Approaches ◽  
Surgical Interventions ◽  
Cure Rates

Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease.

scholarly journals Basal Cell Carcinoma Surgery: Simple Undermining Approach in Two Patients with Different Tumour Locations

2017 ◽  
Vol 5 (4) ◽  
pp. 506-510
Author(s):  
Georgi Tchernev ◽  
Cristiana Voicu ◽  
Mara Mihai ◽  
Tiberiu Tebeica ◽  
Nely Koleva ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Surgical Excision ◽  
Good Prognosis ◽  
Complete Surgical Excision ◽  
Skin Cancers ◽  
Human Malignancy ◽  
Hedgehog Signalling Pathway ◽  
Cure Rates

Basal cell carcinoma (BCC) is the most common human malignancy, accounting for the majority of all non-melanoma skin cancers (NMSC). In the past several decades the worldwide incidence of BCC has constantly been increasing. Even though it is a slow growing tumour that, left untreated, rarely metastasizes, it has a distinctive invasive growth pattern, posing a considerable risk for local invasion and destruction of underlying tissues, such as muscle, cartilage, bone or vital structures. Advanced BCCs include such locally invasive or metastatic tumours. Complete surgical excision is the standard therapy for most uncomplicated BCC cases with good prognosis and cure rates. Treatment of advanced forms of BCCs poses significant therapeutic challenges, most often requiring complicated surgery, radiotherapy, and/or targeted therapies directed towards the sonic hedgehog signalling pathway (SHH). We present two cases of large BCCs located on the scalp and posterior thorax, which underwent surgical excision with clear margins, followed by reconstruction of the defect after extensive undermining of the skin.

scholarly journals Nonsurgical Treatment Options for Basal Cell Carcinoma

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Mary H. Lien ◽  
Vernon K. Sondak
Keyword(s):  
Cost Effectiveness ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
The United States ◽  
Surgical Interventions ◽  
Surgical Options ◽  
Cure Rates

Basal cell carcinoma (BCC) remains the most common form of nonmelanoma skin cancer (NMSC) in Caucasians, with perhaps as many as 2 million new cases expected to occur in the United States in 2010. Many treatment options, including surgical interventions and nonsurgical alternatives, have been utilized to treat BCC. In this paper, two non-surgical options, imiquimod therapy and photodynamic therapy (PDT), will be discussed. Both modalities have demonstrated acceptable disease control rates, cosmetically superior outcomes, and short-term cost-effectiveness. Further studies evaluating long-term cure rates and long-term cost effectiveness of imiquimod therapy and PDT are needed.

scholarly journals Prostatic basal cell carcinoma treated by chemoradiation with weekly cisplatine: case report and literature review

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
S. Ridai ◽  
C. Moustakbal ◽  
A. Lachgar ◽  
H. Jouhadi ◽  
A. Benider ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Urinary Tract ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Lower Urinary Tract Symptoms ◽  
Basal Cell ◽  
Lower Urinary Tract ◽  
Locally Advanced ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Abstract Background Basal cell carcinoma of the prostate is a relatively rare entity. Their evolution is characterized by the frequency of local and/or distant relapses. Due to their rarity, the treatment is not consensual in the literature. We report here a case of Basal cell carcinoma of the prostate in a 40-year-old patient. Case presentation Our patient initially presented an obstructive lower urinary tract symptoms with a normal initial level of prostate specific antigen (PSA) test (3.5 ng/m). The transurethral resection of the prostate (TURP) was in favor of a prostatic basal cell carcinoma with its specific anatomopathological and immunohistochemical characteristics. The prostatic MRI and thoraco-abdominal CT realized after the TURP revealed a tumoral lesion of the prostatic peripheral zone with extra-capsular extension combined with right seminal vesicle invasion and a suggestion of posterior bladder wall adherence. No evidence of visceral or nodal metastases at this point. Considering the tumor being locally advanced, a concurrent chemoradiotherapy with intensity modulated technique was indicated after a multidisciplinary meeting with a 70 Gy total target dose delivered in 35 fractions and weekly Cisplatin. A year and a half after, he developed a cerebellous metastases revealed by intracranial hypertension with no other visceral lesion and complete local remission with the disappearance of the lower urinary tract symptoms and the pain and the appearance of a prostatic atrophy. The PSA level was still on the upper limit of normal. He underwent metastasectomy, and the anatomopathological study was in favor of a cerebellous metastasis of the known BCC. The patient presented postoperatively paraparesis of lower limbs with balance problems for which he was placed in palliative care with indication of postoperative radiation therapy in case of improvement of his general condition. He did not recover and deceased three months later. Conclusions The prostatic basal cell carcinoma is a rare aggressive entity often non-evoked at the clinical or radiological stages because of its unspecific appearance. The diagnostic of these tumors is based on histological examination and a large immunohistochemistry panel. Given its scarity, very few data is available for locally advanced non-metastatic stages treated by radiation therapy. We assess here a good local response with concurrent chemoradiation therapy.

Neoadjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma

2021 ◽  
pp. 100736
Author(s):  
Diya M Sabu ◽  
Jeska Kroes ◽  
Charles Gilham ◽  
Ann Fleming ◽  
Fergal C Kelleher
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Advanced Basal Cell Carcinoma

BOWENOID BASAL CELL CARCINOMA OF THE THUMB: A CASE REPORT AND REVIEW OF THE LITERATURE

Hand Surgery ◽  
2002 ◽  
Vol 07 (02) ◽  
pp. 295-298 ◽  
Author(s):  
M. Galeano ◽  
M. Colonna ◽  
M. Lentini ◽  
F. Stagno D'Alcontres
Keyword(s):  
Case Report ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Basal Layer ◽  
Rare Entity ◽  
Review Of The Literature ◽  
Skin Malignancy ◽  
Root Sheath ◽  
Common Skin

Basal cell carcinoma (BCC) is the most common skin malignancy arising from cells of the basal layer of the epithelium or from the external root sheath of the hair follicle. BCC of the digit is a rare entity. The article presents one such case of bowenoid BCC of the thumb which required amputation at the MP joint.

Sign in / Sign up

Export Citation Format

Share Document